Windlas Biotech Limited reported a 19% year-on-year increase in revenue to ₹904 crores for the financial year ended March 31, 2026, driven by strong performance across its verticals. The company achieved its highest post-listing EPS of ₹31.60 and maintained ROCE and ROE above the 25% mark. For the quarter ended March 31, 2026, revenue grew 18% year-on-year to ₹238 crores, marking the 13th consecutive quarter of record revenue.

Financial Performance

The company’s adjusted EBITDA for FY26 stood at ₹121 crores, representing a margin of 13.4%, while Profit After Tax (PAT) was ₹83 crores, or 9.2%. In Q4 FY26, adjusted EBITDA reached ₹33 crores with a margin of 13.6%, and PAT was ₹23 crores. On a reported basis, EBITDA grew 11% to ₹105 crores and PAT rose 9% to ₹66 crores for the full year. The business generated ₹105 crores of net operating cash flows, closing the year with a net liquidity position of ₹251 crores.

Segment Performance

The Generic Formulations CDMO vertical achieved revenues of ₹664 crores in FY26 and ₹176 crores in Q4 FY26, reflecting 20% year-on-year growth. The Trade Generics and Institutional vertical grew 13% to ₹195 crores in FY26, while the export vertical saw a significant 40% growth to ₹46 crores in FY26, with Q4 revenue increasing 67% year-on-year to ₹17 crores.

Strategic Developments

During the year, Plant 4 and Plant 5, the injectable facility, received GMP certification from the Philippines. Plant 6 achieved mechanical completion and remains on track for commercialization by H1 of FY27. The Board has proposed a dividend of ₹13 crores, or ₹6.3 per share, for FY26. The management emphasized its focus on capital efficiency, operational discipline, and expanding its client base to drive long-term value.

Windlas Biotech has announced its audited financial results for the quarter and financial year ended March 31, 2026. The company reported its highest ever revenue from operations at Rs 904.09 crore for FY26, a growth of 19% compared to Rs 759.88 crore in the previous year. Profit for the year stood at Rs 66.44 crore, registering a growth of 9% year-on-year from Rs 60.95 crore. The Board of Directors has recommended a dividend of Rs 6.30 per equity share of the face value of Rs 5 each, subject to shareholder approval.

For the quarter ended March 31, 2026, revenue from operations stood at Rs 238.50 crore, an increase of 18% from Rs 202.71 crore in the corresponding quarter of the previous year. Profit for the quarter was Rs 16.02 crore. Basic earnings per share (EPS) for FY26 rose to Rs 31.59 from Rs 29.03 in the previous year. The company reported a net liquidity position and remained net debt free.

Financial Performance

The company achieved its highest ever Adjusted EBITDA of Rs 121 crore in FY26, a 26% YoY growth, with a margin of 13.4%. Reported EBITDA for the year was Rs 105 crore. The Board meeting was held on May 21, 2026, to consider and approve the financial results.

Operational Highlights

The Generic Formulations CDMO vertical recorded its highest ever revenue of Rs 664 crore in FY26, a 20% YoY growth, contributing 73% to the consolidated revenue. The Trade Generics & Institutional vertical reported revenue of Rs 195 crore, up 13% YoY. The Exports vertical grew by 40% to Rs 46 crore during the fiscal year.

During the year, the company completed a buyback of 470,000 fully paid-up equity shares at a price of Rs 1,000 per share, aggregating to Rs 47 crore.